Atazanavir (BMS-232632) is a new protease inhibitor that is being developed by Bristol-Myers Squibb. Most currently licensed protease inhibitors (PIs) usually cause increased levels of lipids — cholesterol and triglycerides — in PHAs who use them. Atazanavir offers several advantages over currently licensed PIs, including the following:
Atazanavir has potential to be used as a booster — much in the same way that the PI ritonavir (Norvir) is often used to boost levels of other PIs such as:
One possible drawback to atazanavir is that users can develop higher-than-normal levels of the waste product bilirubin in their blood. The long-term effect of this is not yet clear.Atazanavir (BMS-232632) is a new protease inhibitor that is being developed by Bristol-Myers Squibb. Most currently licensed protease inhibitors (PIs) usually cause increased levels of lipids — cholesterol and triglycerides — in PHAs who use them. Atazanavir offers several advantages over currently licensed PIs, including the following:
Atazanavir has potential to be used as a booster — much in the same way that the PI ritonavir (Norvir) is often used to boost levels of other PIs such as:
One possible drawback to atazanavir is that users can develop higher-than-normal levels of the waste product bilirubin in their blood. The long-term effect of this is not yet clear.
20020131
CATE12411
Copyright © 2002 - TreatmentUpdate. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, The Canadian AIDS Treatment Information Exchange, 555 Richmond St. West, Suite 505, Box 1104, Toronto, ON, M5V 3B1 • Phone: 416-203-7122 • Toll Free: 1-800-263-1638 • Fax: 416-203-8284 http://www.catie.ca.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.